Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based BiomarkersHAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood-based biomarkers.
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson SyndromeMNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board memberTIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.
Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023Company to be in San Francisco January 8-12, 2023, during 41st Annual J.P. Morgan Health Care Conference
Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial DiseasesFirst in human clinical study provides proof-of-concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate effects of large-scale mitochondrial DNA (mtDNA) deletion syndromes
Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo
Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Technology (MAT) to treat mitochondrial diseases, announced today the publication of preclinical data demonstrating that mitochondrial augmentation of CD34+ cells confers functional benefit and that mitochondrial transfer occurs between hematopoietic cells in vivo. The dose-dependent ability of isolated mitochondria to enter healthy or diseased human CD34+ cells, termed mitochondrial augmentation, was demonstrated for the first time.
